BioLife Solutions

BioLife Solutions, Inc. engages in the development, manufacture and marketing of bio preservation tools for cells and tissues. Its product offerings include proprietary hypothermic storage and cryopreservation freeze media products for cells, tissues, and organs, generic blood stem cell freezing and cell thawing media products and custom product formulation and custom packaging services. The company was founded by Boris Rubinsky in 1987 and is headquartered in Bothell, WA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

BioLife Solutions reports record revenue and projects strong growth

BioLife Solutions delivered strong financial performance in Q4 2022, with record revenue and growth across key revenue platforms.
Despite challenges in operating expenses and gross margin, the company remains optimistic about future growth and profitability.
By focusing on high-margin revenues, supply chain enhancements, and allogeneic therapies, BioLife is strategically positioned for long-term success.

BioLife Solutions reports revenue growth and strategic business evaluation

BioLife Solutions reported solid Q1 2023 performance with revenue growth and improved gross margin, despite short-term EBITDA challenges.
The company is strategically evaluating underperforming businesses while focusing on high-margin recurring revenue streams for future growth.
CEO's balanced approach of maintaining strengths and exploring new projects signals a commitment to sustainable profitability and innovation.
BioLife's emphasis on efficiency and strategic planning positions it well for navigating market uncertainties and driving long-term success.

BioLife Solutions reports Q2 revenue decline, focuses on strategic growth

BioLife Solutions navigated challenges in Q2 2023 with a strategic focus on higher-margin streams and a strong pipeline for growth.
Despite a decrease in revenue and challenges in key markets, the company's divestiture plans and revenue guidance reflect confidence in future performance.
Analysts' concerns about capacity constraints and operational challenges highlight areas for improvement and strategic focus for BioLife Solutions.

BioLife Solutions faces revenue decline in Q3 but eyes market growth

BioLife Solutions navigated challenges in Q3 2023 with a decline in revenue and negative adjusted EBITDA, but remains optimistic about its market position and potential for revenue recovery. Strategic divestiture plans and a focus on core products aim to drive profitability and growth.

BioLife Solutions reports 11% revenue decrease in 2023

BioLife Solutions navigated revenue challenges in 2023, with a focus on higher margin revenue streams and operational efficiency.
Despite revenue declines, the company remains optimistic about future growth opportunities in the cell processing sector.
Proactive supply chain management and a diversified supplier base position BioLife well to mitigate risks and ensure operational continuity.
Strategic plans to divest underperforming product lines and optimize operations indicate a path towards improved financial performance.

BioLife Solutions excels in Q3, shifts focus to high-margin CGT tools

BioLife Solutions demonstrated robust performance in Q3 2024, driven by strong revenue growth and strategic divestment decisions.
The company's focus on becoming a pure-play CGT tools provider and emphasis on high-margin products signal a clear strategic direction.
While facing challenges in transitioning its business model, BioLife is well-equipped to capitalize on opportunities in the growing biopreservation market.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BOTHELL, Wash., June 15, 2021 /PRNewswire/ --  BioLife Solutions , Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of class-defining bioproduction products and services for cell and gene therapies and the broader biopharma market, today announced the launch of its new corporate brand identity, redesigned logo, and website.

BioLife Solutions Adopts New Brand Identity

BOTHELL, Wash., May 19, 2021 /PRNewswire/ --  BioLife Solutions , Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of class-defining bioproduction products and services for cell and gene therapies and the broader biopharma market, today announced the promotion of Caitlin Rice to the leadership position of Global Vice President, Customer Service, reporting to Dusty Tenney, President and Chief Operating Officer.

BioLife Solutions Announces Promotion of Caitlin Rice to Global Vice President, Customer Service

BioLife Solutions, Inc. (BLFS) CEO Mike Rice on Q1 2021 Results - Earnings Call Transcript

BOTHELL, Wash., May 13, 2021 /PRNewswire/ -- BioLife Solutions , Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of class-defining bioproduction products and services for cell and gene therapies and the broader biopharma market, today announced financial results for the three months ended March 31, 2021.

BioLife Solutions Announces First Quarter 2021 Financial Results

BOTHELL, Wash., May 6, 2021 /PRNewswire/ --  BioLife Solutions , Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of a portfolio of class-defining bioproduction products and services for cell and gene therapies and the broader biopharma market, today announced that the Company's first quarter 2021 financial results will be released after market close on Thursday, May 13, 2021, and that the Company will host a conference call and live webcast at 4:30 p.m.

BioLife Solutions to Report First Quarter 2021 Financial Results and Provide Business Update on May 13, 2021

BioLife Solutions, Inc. (BLFS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: BioLife Solutions, Inc. (BLFS) Q1 Earnings Expected to Decline

BOTHELL, Wash., May 3, 2021 /PRNewswire/ -- BioLife Solutions , Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of a portfolio of class-defining bioproduction products and services for cell and gene therapies and the broader biopharma market, today announced that it has closed the previously announced acquisition of Stirling Ultracold ("Stirling"), a privately held manufacturer of ultra-low temperature ("ULT") mechanical freezers.

BioLife Solutions Announces Closing of Stirling Ultracold Acquisition and Expanded Partnership with Leading Global Biopharma CDMO

BOTHELL, Wash., April 15, 2021 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of a portfolio of class-defining bioproduction products and services for cell and gene therapies, today announced that it has launched a new line of high capacity controlled rate freezers (HCRF), with an initial shipment to a leading cell therapy company.

BioLife Solutions Launches New High Capacity Controlled Rate Freezer Line with First Shipment to a Leading Cell Therapy Developer

Hill-Rom Hlds

HRC vs. BLFS: Which Stock Is the Better Value Option?

HRC or BLFS: Which Is the Better Value Stock Right Now?

BOTHELL, Wash., April 6, 2021 /PRNewswire/ --  BioLife Solutions , Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of a portfolio of class-defining bioproduction products and services for cell and gene therapies, today announced that it has appointed Amy DuRoss, chief executive officer of Vineti, and Rachel Ellingson, senior vice president and chief strategy officer at Zimmer Biomet to its board of directors effective immediately.

BioLife Solutions Appoints Two New Independent Board Directors

The stock price of BioLife Solutions Inc (NASDAQ: BLFS) increased by over 15% pre-market. This is why it happened.

BLFS Stock Price Increases Over 15% Pre-Market: Why It Happened

BioLife Solutions, Inc. (BLFS) CEO Mike Rice on Q4 2020 Results - Earnings Call Transcript

Shares of BioLife Solutions (NASDAQ:BLFS) rose 9.7% in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share were down 0.00% year over year to ($0.01), which beat the estimate of ($0.02).

BioLife Solutions: Q4 Earnings Insights

COLUMBUS, Ohio, March 22, 2021 /PRNewswire/ -- Stirling Ultracold, an Ohio-based manufacturer and provider of the most energy efficient, sustainable ultra-low temperature (ULT) biorepositories has entered into a definitive agreement to merge with BioLife Solutions (NASDAQ: BLFS), a leading provider of bioproduction products and services for the Gene and Cell Therapy (GCT) markets. Stirling Ultracold is backed by the Ohio Innovation Fund (OIF), with OIF Managing Director Bill Baumel serving on the board, the Strategic Committee alongside CEO Dusty Tenney, and acting as the Seller Representative in this transaction -- OIF Principal Faith Voinovich led the reverse diligence on BioLife for Stirling.

Stirling Ultracold to Merge with BioLife Solutions, the Leader in Gene and Cell Therapy Bioproduction Tools and Services

ATHENS, Ohio, March 22, 2021 /PRNewswire/ -- Stirling Ultracold, a privately-held innovative developer and manufacturer of ultra-low temperature (ULT) freezers, today announced it has signed a definitive agreement to merge into BioLife Solutions (NASDAQ: BLFS) to combine expertise and expand individual product offerings for biopharma research and life science customers. Following the early second quarter 2021 close of this transaction, BioLife intends to keep the Stirling Ultracold brand in-tact and maintain existing staff in Athens, Ohio – noting business-as-usual for existing customers and partners.

Stirling Ultracold Announces Merger Agreement with BioLife Solutions to Further Support Life-Science Industry with Expertise in Ultra-Low Temperature Storage

BOTHELL, Wash., March 22, 2021 /PRNewswire/ --  BioLife Solutions , Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of a portfolio of class-defining bioproduction products and services for cell and gene therapies, today announced financial results for the fourth quarter and year ended December 31, 2020.

BioLife Solutions Announces Fourth Quarter and Full Year 2020 Financial Results

BOTHELL, Wash., March 22, 2021 /PRNewswire/ --  BioLife Solutions , Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of a portfolio of class-defining bioproduction products and services for cell and gene therapies, today announced the signing of a definitive merger agreement to acquire Global Cooling, Inc., operating as Stirling Ultracold ("Stirling"), a privately held manufacturer of ultra-low temperature ("ULT") mechanical freezers.

BioLife Solutions to Acquire Stirling Ultracold in an All-Stock Merger

BOTHELL, Wash., March 10, 2021 /PRNewswire/ -- BioLife Solutions , Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of a portfolio of class-defining bioproduction products and services for cell and gene therapies, today announced that the Company's fourth quarter and full year 2020 financial results will be released after market close on Monday, March 22, 2021, and that the Company will host a conference call and live webcast at 4:30 p.m.

BioLife Solutions to Report Fourth Quarter and Full Year 2020 Financial Results and Provide Business Update on March 22, 2021

HRC vs. BLFS: Which Stock Should Value Investors Buy Now?

STAAR Surgical

TG Therapeutics

Despite MedTech industry's bright prospects in 2021, investors should be wary of stocks like BLFS, STAA and TGTX, given their unfavorable Zacks Rank and weak fundamentals.

3 Soaring MedTech Stocks That Might Lose Ground in 2021

BioLife Solutions, Inc.'s (BLFS) CEO Michael Rice on Q3 2020 Results - Earnings Call Transcript

BOTHELL, Wash., Nov. 5, 2020 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of a portfolio of class-defining bioproduction products and services for cell and gene therapies, today announced financial results for the...

BioLife Solutions Announces Third Quarter 2020 Financial Results

BOTHELL, Wash., Oct. 14, 2020 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of a portfolio of class-defining bioproduction tools and services for cell and gene therapies, today announced its recently acquired SciSafe...

BioLife Solutions SciSafe Division Secures $2.7 Million Cold Chain and Storage Contract for COVID-19 Vaccines

Q2 2020 was a stellar quarter for BLFS in terms of revenue generation and new customer onboarding.

News for BioLife Solutions Stock (BLFS)